TAAR1 and schizophrenia: Ulotaront (SEP‐363856),12 another small molecule antipsychotic drug targeting TAAR1 and 5‐HT1AR, developed by Sunovion Pharmaceuticals and PsychoGenics, was granted by the US Food and Drug Administration in 2019 as a non‐dopamine receptor‐targeted anti‐schizophrenia breakthrough therapy (Figure 1A).13